Eisai Alzheimer Drug Shows Promise in Injected-At-Home Form

Novartis Spinoff Sandoz to Start Trading as Standalone Drugmaker

Eisai’s Alzheimer’s Drug Wins Approval in Japan, Following US

Eisai Azheimer’s Drug Set to Win Japanese Approval, Following US

China Drug-Price Negotiations Offers Glimpse Into Future for Companies in US

Medicare Proposes Expanding Patient Access to Alzheimer’s Scans

Lilly Applies for Alzheimer’s Drug’s US Approval After Trial Success

Eisai Appoints CEO’s 34-Year-Old Son to Lead Global Alzheimer Drug Program

How a Japanese Drugmaker Clinched Win Over Alzheimer’s

Eisai Alzheimer's Drug Gets Full US Approval, Widening Access to the Therapy

Eisai, Biogen Clinch FDA Advisers’ Support for Alzheimer’s Drug

AstraZeneca’s Japan Partner to Go Solo on Future Cancer Drugs